About this episode

The episode features an interview with Prof Dr Sibylle Loibl discussing advancements in the treatment of HER2-positive metastatic breast cancer.

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics: Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00) Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35) Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01) Targeting the PI3K signaling pathway in HER2-positive mBC (11:08) Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53) Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44) Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54) Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03) CME information and select publications

People in this episode

Host: Dr Neil Love

Guest: Prof Dr Sibylle Loibl

Topics covered

• HER2-positive metastatic breast cancer
• first-line therapy
• maintenance therapy
• treatment outcomes
• endocrine therapy
• PI3K signaling pathway
• patient management

Keywords

• HER2-positive
• metastatic breast cancer
• trastuzumab deruxtecan
• pertuzumab
• endocrine therapy
• PI3K signaling
• patient outcomes
• CME

Mentioned in this episode

Organizations: DESTINY-Breast09

Products: trastuzumab deruxtecan, pertuzumab

More episodes of Oncology Today with Dr Neil Love

• Endometrial Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting · July 20, 2026 · 1h 30m
• For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress · July 16, 2026 · 1h 58m
• Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting · July 15, 2026 · 2h 1m
• HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review · July 14, 2026 · 28 min
• Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances · July 13, 2026 · 58 min
• Endometrial Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women’s Cancer · July 12, 2026 · 15 min

Explore listener stats, chart rankings, contacts and more on the Oncology Today with Dr Neil Love podcast page.